Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma
Lance Heilbrun
Anticancer research, 2012
View PDFchevron_right
Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study
Kun-Pin Hsieh
The Kaohsiung Journal of Medical Sciences, 2017
View PDFchevron_right
A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities
Teresa Gamucci
Clinical Colorectal Cancer, 2008
View PDFchevron_right
Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
Peter Preusser
Journal of Clinical Oncology, 2008
View PDFchevron_right
Combined Therapy with Weekly Irinotecan, Infusional 5-Fluorouracil and the Selective COX-2 Inhibitor Rofecoxib Is a Safe and Effective Second-Line Treatment in Metastatic Colorectal Cancer
Teresa Gamucci, Francesco Torino
The Oncologist, 2005
View PDFchevron_right
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study
Eugene Frenkel
International Journal of Cancer, 2003
View PDFchevron_right
Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicenter Experience
Sergio Stinco
Clinical Colorectal Cancer, 2006
View PDFchevron_right
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study
Arkom Cheirsilpa
World Journal of Gastroenterology, 2011
View PDFchevron_right
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
Carla Rabitti
British Journal of Cancer, 2006
View PDFchevron_right
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH
Dawn Dawson
Cancer Epidemiology Biomarkers & Prevention, 2018
View PDFchevron_right
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Matthias Mueser
New England Journal of Medicine, 2004
View PDFchevron_right
The Relationship of Cyclooxygenase -2 (COX-2) Expression with Clinical Presentation, Staging, and Degree of Differentiation in Colorectal Cancer
Julianus A B O Y A M A N Uwuratuw
International Journal of Sciences: Basic and Applied Research, 2017
View PDFchevron_right
Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
Yoshito Komatsu
Japanese Journal of Clinical Oncology, 2008
View PDFchevron_right
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum
Sachio Fushida
Oncology Reports, 2012
View PDFchevron_right
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial
andres cervantes
British Journal of Cancer, 2008
View PDFchevron_right
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence
Elham Rahme
Gastroenterology, 2003
View PDFchevron_right
COX-2 inhibitors: a potential target for drug therapy in the management of colorectal cancer
Kamarul Ariffin Khalid
The Medical journal of Malaysia, 1999
View PDFchevron_right
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Matthew Seymour
The Lancet, 2011
View PDFchevron_right
A Review: Role of Cyclooxygenase- 2 Inhibitors in Treatment of Colorectal Cancer
Ganesh Mhaske
Journal of Current Pharma Research
View PDFchevron_right
Update on Novel Strategies to Optimize Cetuximab Therapy in Patients with Metastatic Colorectal Cancer
Francisco Javier Peña Ramos
Clinical Colorectal Cancer, 2008
View PDFchevron_right
Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer
Labile Soumaoro
Clinical Cancer Research, 2004
View PDFchevron_right
Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer
Thomas Herrmann
Anticancer research
View PDFchevron_right
Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma
Eman Emam, Jaudah Al-maghrabi, Abdulrahman Sibiany
World Journal of Gastroenterology, 2012
View PDFchevron_right
Clinicopathologic significance of cyclooxygenase-2 overexpression in colorectal adenocarcinoma
Si-Hyong Jang
Basic and Applied Pathology, 2010
View PDFchevron_right
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Heinz-josef Lenz
JAMA, 2017
View PDFchevron_right
Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
Allen Cohn, Thomas Cartwright
Clinical Colorectal Cancer, 2008
View PDFchevron_right
Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and Intravenous Bolus 5-Fluorouracil for Metastatic Colorectal Cancer: Pooled Analysis of Two Consecutive Southern Italy Cooperative Oncology Group Trials
Donato Natale
Clinical Colorectal Cancer, 2005
View PDFchevron_right
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
Rune Smaaland
British journal of cancer, 2004
View PDFchevron_right